Pharmacology of NO:cGMP signal transduction

Clinical Trial

M J Lohse et al. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jul.

. 1998 Jul;358(1):111-2.

doi: 10.1007/pl00005230.

No abstract available

Comment on

The use of nitric oxide donors in pharmacological studies.
Feelisch M. Feelisch M. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jul;358(1):113-22. doi: 10.1007/pl00005231. Naunyn Schmiedebergs Arch Pharmacol. 1998. PMID: 9721012 Review.
Modulators of soluble guanylyl cyclase.
Koesling D. Koesling D. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jul;358(1):123-6. doi: 10.1007/pl00005232. Naunyn Schmiedebergs Arch Pharmacol. 1998. PMID: 9721013 Review. No abstract available.
Nitric oxide synthases: catalytic function and progress towards selective inhibition.
Mayer B, Andrew P. Mayer B, et al. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jul;358(1):127-33. doi: 10.1007/pl00005233. Naunyn Schmiedebergs Arch Pharmacol. 1998. PMID: 9721014 Review.
Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects.
Smolenski A, Burkhardt AM, Eigenthaler M, Butt E, Gambaryan S, Lohmann SM, Walter U. Smolenski A, et al. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jul;358(1):134-9. doi: 10.1007/pl00005234. Naunyn Schmiedebergs Arch Pharmacol. 1998. PMID: 9721015 Review.
Cyclic nucleotide-gated channels--mediators of NO:cGMP-regulated processes.
Biel M, Sautter A, Ludwig A, Hofmann F, Zong X. Biel M, et al. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jul;358(1):140-4. doi: 10.1007/pl00005235. Naunyn Schmiedebergs Arch Pharmacol. 1998. PMID: 9721016 Review.